Core Viewpoint - Beijing Wuhua Boao Pharmaceutical Co., Ltd. (Wuhua Boao) is preparing for an IPO on the Hong Kong Stock Exchange, focusing on innovative natural drugs for treating metabolic diseases and cancers, with a valuation of 4.038 billion yuan prior to the IPO [2][11]. Company Overview - Wuhua Boao was established in 2010 and specializes in high-barrier innovative drug research and development, industrialization, and commercialization, particularly targeting major diseases such as metabolic disorders and malignant tumors [3]. - The company has developed a drug delivery system (DDS) aimed at overcoming technical bottlenecks in drug delivery [3]. Key Products - The core product "Sangbongen®" (WH001) is a Class 1 innovative traditional Chinese medicine approved for market in March 2020, recognized as China's first and only approved natural drug for blood sugar control, and also the world's first plant-derived effective component for lowering blood sugar [3]. - Wuhua Boao is expanding its treatment indications from diabetes to include obesity, MASH, and PCOS, aiming to provide systematic treatment capabilities for complex metabolic diseases [4]. Research and Development Pipeline - The company has eight drug candidates in development, including three core products: WH007, WH006, and WH002 [4]. - WH007 is a Class 2.3 modified new drug for treating polycystic ovary syndrome (PCOS), currently the only natural drug in clinical development for PCOS in China, with Phase II trials approved to start in December 2025 [7]. - WH006 is a Class 2.3 modified new drug for adult obesity, with Phase II clinical trials initiated in August 2025, also the only natural drug in clinical Phase II for obesity in China [8]. - WH002 is a targeted lipid emulsion for treating Luminal breast cancer, with Phase II trials expected to complete in November 2025 and Phase III trials anticipated to start in 2026 [9]. Financial Performance - For the fiscal year 2024 and the nine months ending September 30, 2025, Wuhua Boao reported revenues of 208 million yuan and 207 million yuan, respectively, with gross margins of 72.1% and 74.1% [10]. - The adjusted net losses for the same periods were 88.81 million yuan and 36.85 million yuan, indicating a narrowing loss margin [10].

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Beijing Wehand-Bio Pharmaceutical Co., Ltd.* 北 京 五 和 博 澳 藥 業 股 份 有 限 公 司 ...

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本 的內容概不負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Wehand-Bio Pharmaceutical Co., Ltd.* 北 京 五 和 博 澳 藥 業 股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 重 要 提 示 閣下如對本文件任何內容有任何疑問，應諮詢獨立專業意見。 Beijing Wehand-Bio Pharmaceutical Co., Ltd.* 北 京 五 和 博 澳 藥 業 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、本公司的獨家保薦人、保薦人兼整體協調 ...